- Home
- SAVA vs FURY Comparison
SAVA vs FURY Comparison
Compare SAVA & FURY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- FURY
- Stock Information
- Founded
- SAVA 1998
- FURY 2008
- Country
- SAVA United States
- FURY Canada
- Employees
- SAVA N/A
- FURY N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- FURY Precious Metals
- Sector
- SAVA Health Care
- FURY Basic Materials
- Exchange
- SAVA Nasdaq
- FURY Nasdaq
- Market Cap
- SAVA 102.4M
- FURY 84.1M
- IPO Year
- SAVA N/A
- FURY N/A
- Fundamental
- Price
- SAVA $2.11
- FURY $0.69
- Analyst Decision
- SAVA Hold
- FURY Strong Buy
- Analyst Count
- SAVA 1
- FURY 2
- Target Price
- SAVA $2.00
- FURY $1.40
- AVG Volume (30 Days)
- SAVA 517.9K
- FURY 633.2K
- Earning Date
- SAVA 11-06-2025
- FURY 11-11-2025
- Dividend Yield
- SAVA N/A
- FURY N/A
- EPS Growth
- SAVA N/A
- FURY N/A
- EPS
- SAVA N/A
- FURY N/A
- Revenue
- SAVA N/A
- FURY N/A
- Revenue This Year
- SAVA N/A
- FURY N/A
- Revenue Next Year
- SAVA N/A
- FURY N/A
- P/E Ratio
- SAVA N/A
- FURY N/A
- Revenue Growth
- SAVA N/A
- FURY N/A
- 52 Week Low
- SAVA $1.15
- FURY $0.35
- 52 Week High
- SAVA $33.98
- FURY $0.73
- Technical
- Relative Strength Index (RSI)
- SAVA 44.15
- FURY 68.85
- Support Level
- SAVA $2.12
- FURY $0.64
- Resistance Level
- SAVA $2.19
- FURY $0.73
- Average True Range (ATR)
- SAVA 0.10
- FURY 0.04
- MACD
- SAVA -0.02
- FURY 0.01
- Stochastic Oscillator
- SAVA 6.45
- FURY 83.36
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.